uniQure N.V. (QURE)
QURENASDAQ-GSBiotechnology: Pharmaceutical Preparations
$23.81
-0.8200 (-3.33%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.67bn
- P/E
- –
- EPS, last 4 quarters
- $-3.51
- Dividend yield
- –
- Day range
- –
- 52-week range
- $8.73 to $51.72
- Average volume
- –
- Previous close
- $24.63
Analysts
11 coveringBuy8 buy, 3 hold, 0 sell
Targets a year out average $54.29, +128.0% from here
Earnings
next estimate $-0.8800Next report
Dec 2025
+39.8%
Mar 2026
+3.4%
Jun 2026
-50.6%
Sep 2026
-4.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $5.57m | $3.56m | $5.84m | $5.20m |
| Gross profit | $5.13m | $3.34m | $5.49m | $4.96m |
| Operating income | -$51.12m | -$45.72m | -$52.20m | -$52.98m |
| Net income | -$37.09m | -$53.53m | -$81.06m | -$61.22m |
Last four quarters: revenue $20.17m, margin -1154.8%, free cash flow -$192.96m
News
8 latest- QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now? Zacks · 11 hours ago
- uniQure (QURE) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 4, 2026
- UniQURE's Q3 Loss Narrows To $60 Mln With Rising Expenses As Clinical Portfolio Advances RTTNews · Nov 4, 2026
- uniQure Q3 Earnings Call HighlightsMarketBeat · Nov 4, 2026
- uniQure N.V. Reports FDA Priority Review of BLA for AMT-130 and Third Quarter 2026 Financial ResultsFintel · Nov 4, 2026
- uniQure (QURE) Reports Q3 Loss, Misses Revenue EstimatesZacks · Nov 4, 2026
- FDA Accepts UniQure's BLA For Huntington's Gene Therapy; PDUFA Date In May '27 RTTNews · Nov 3, 2026
- UniQure's Ifezuntirgene Inilparvovec BLA Gets FDA Priority Review Acceptance RTTNews · Nov 2, 2026
The company
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. The approvals of uniQure's gene therapy for hemophilia B - an historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- uniqure.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.